RegulatoryAug 13, 2026, 07:16 AM
Liminatus Pharma Transfers to Nasdaq Capital Market, Gets Bid Price Extension
AI Summary
Liminatus Pharma, Inc. announced its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026. The Nasdaq Hearings Panel also granted the company an extension until September 3, 2026, to regain compliance with the minimum bid price requirement. The company intends to take necessary actions to meet this requirement and maintain its Nasdaq listing.
Key Highlights
- Liminatus Pharma common stock transferred from Nasdaq Global Market to Nasdaq Capital Market.
- The transfer was effective August 4, 2026.
- Nasdaq Hearings Panel granted an extension for the company to comply with the minimum bid price requirement.
- Liminatus Pharma has until September 3, 2026, to demonstrate compliance with the Bid Price Rule.
- The company's common stock will continue to trade on the Nasdaq Capital Market under ticker "LIMN".
Price Impact
More from LIMN